GlassScriptPhysician profile
John T Butcher
NPI 1275510810
$2,841.10
in general payments reported to CMS, 2019-2025
27 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $344 · 2021: $194 · 2022: $130 · 2023: $437 · 2024: $774 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $554.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $525.85 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $438.54 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $168.47 | 2024-2025 | Voquezna |
| Abbott Laboratories | $157.38 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $114.39 | 2020-2021 | |
| Lilly USA, LLC | $103.05 | 2023-2025 | Mounjaro, Zepbound |
| Horizon Therapeutics Plc | $81.79 | 2019 | |
| Abbvie INC. | $80.05 | 2021-2024 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $78.78 | 2023-2025 | |
| Antares Pharma, INC. | $68.35 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Glaxosmithkline, LLC. | $57.76 | 2020-2025 | Arexvy, Shingrix |
| Pfizer INC. | $55.95 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $47.89 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $44.85 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $42.87 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $37.07 | 2025 | Capvaxive, Gardasil 9 |
| Metuchen Pharmaceuticals | $29.80 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $25.97 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $25.40 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $18.51 | 2019 | |
| Vivus LLC | $16.99 | 2024 | Qsymia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.95 | 2021 | |
| Astellas Pharma US INC | $13.81 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $13.51 | 2024 | Quviviq |
| Assertio Therapeutics, INC. | $12.49 | 2019 | |
| Allergan, INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Butcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.